The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy
Paolo F. Caimi, Kirit M. Ardeshna, Erin Reid, Weiyun Z. Ai, Matthew A. Lunning, Jasmine Zain, Melhem Solh, Brad S. Kahl, Mehdi Hamadani
Topics & Concepts
ImmunoconjugateChimeric antigen receptorCD19MedicineAntibodyAntibody-drug conjugateCancer researchInternal medicineCD22OncologyImmunotherapyImmunologyMonoclonal antibodyCancerCAR-T cell therapy researchBiosimilars and Bioanalytical MethodsBiotechnology and Related Fields